Application Nr Approved Date Route Status External Links
ANDA079135 None Oral None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

Indications And Usage Trandolapril And Verapamil Hydrochloride Extended-Release Tablets Are Indicated For The Treatment Of Hypertension. This Fixed Combination Drug Is Not Indicated For The Initial Therapy Of Hypertension (See Dosage And Administration ). In Using Trandolapril And Verapamil Hydrochloride Extended-Release Tablets, Consideration Should Be Given To The Fact That An Angiotensin Converting Enzyme Inhibitor, Captopril, Has Caused Agranulocytosis, Particularly In Patients With Renal Impairment Or Collagen Vascular Disease, And That Available Data Are Insufficient To Show That Trandolapril Does Not Have Similar Risk (See Warnings - Neutropenia/agranulocytosis ).

All Formulated Excipients (0 Total)

None

Active Ingredients ( 2 Total)

Comments